|
TOP
|
|
Herceptin(三)
|
athy. |
ACAnthracycline (doxorubicin) and cyclophosphamide → Paclitaxel+Herceptin |
2% (32/1677) |
0.4% (7/1600) |
|
3 |
Chemo → Herceptin |
2% (30/1678) |
0.3% (5/1708) |
|
4 |
AC → Docetaxel+Herceptin |
2% (20/1068) |
0.3% (3/1050) |
|
4 |
Docetaxel+Carbo+Herceptin |
0.4% (4/1056) |
0.3% (3/1050) |
Table 2: Incidence of Cardiac DysfunctionCongestive heart failure or significant asymptomatic decrease in LVEF. in Metastatic Breast Cancer Studies
|
|
|
Incidence |
|
|
|
NYHA I‑IV |
NYHA III‑IV |
|
Study |
Event |
Herceptin |
Control |
Herceptin |
Control |
|
5 (AC)Anthracycline (doxorubicin or epirubicin) and cyclophosphamide. |
Cardiac Dysfunction |
28% |
7% |
19% |
3% |
|
5 (paclitaxel) |
Cardiac Dysfunction |
11% |
1% |
4% |
1% |
|
6 |
Cardiac DysfunctionIncludes 1 patient with fatal cardiomyopathy. |
7% |
N/A |
5% |
N/A |
Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion included nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia. [see Adverse Reactions (6.1)]
In postmarketing reports, serious and fatal infusion reactions have been reported. Severe reactions which include bronchospasm, anaphylaxis, angioedema, hypoxia, and severe hypotension, were usually reported during or immediately following the initial infusion. However, the onset and clinical course were variable including progressive worsening, initial improvement followed by clinical deterioration, or delayed post‑infusion events with rapid clinical deterioration. For fatal events, death occurred within hours to days following a serious infusion reaction.
Interrupt Herceptin infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered, which may include: epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen. Patients should be eva luated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be strongly considered in all patients with severe infusion reactions.
There are no data regarding the most appropriate method of identification of patients who may safely be retreated with Herceptin after experiencing a severe infusion reaction. Prior to resumption of Herceptin infusion, the majority of patients who experienced a severe infusion reaction were pre‑medicated with antihistamines and/or corticosteroids. While some patients tolerated Herceptin infusions, others had recurrent severe infusion reactions despite pre‑medications.
Herceptin can cause fetal harm when administered to a pregnant woman. In post marketing reports, use of Herceptin during pregnancy resulted in cases o |
